{"name":"Neurimmune AG","slug":"neurimmune-ag","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Neuroscience","slug":"neuroscience","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"oncology","drugs":[{"name":"ALXN2220","genericName":"ALXN2220","slug":"alxn2220","indication":"Parkinson's disease","status":"phase_3"}]}],"pipeline":[{"name":"ALXN2220","genericName":"ALXN2220","slug":"alxn2220","phase":"phase_3","mechanism":"ALXN2220 is a monoclonal antibody that targets phosphatidylserine on apoptotic cells to enhance their clearance and reduce neuroinflammation.","indications":["Parkinson's disease","Alzheimer's disease (exploratory)"],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMimgFBVV95cUxNTllOcGtwUGc1TXEwdFBHXy1wV1VPcWQ3eEZaWkpaX1FxV1hLSEZDYWprdHM3ZU52bEVYbFJoa0hfUGtCOHlIN0o5UEZjTzNhMTEwWjg4cV9CUl9mTE1ORXVZLWhZb3I3YTgxZEROeFNpV01JNUxBczRJRTlEbVNabXd4M1k5UWhSNzNmQWk5VmwxRTFidWd3YTVB?oc=5","date":"2025-12-05","type":"deal","source":"The Pharma Letter","summary":"Neurimmune expands collaboration with AstraZeneca - The Pharma Letter","headline":"Neurimmune expands collaboration with AstraZeneca","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMinwFBVV95cUxQclB6ZVI0dzF4QVp5dEViOXdfUFE0a2VzVjVnc0QwbzFnblFXbnRsRi12UFlhMHpBQVljMkdVTWFSTXJVajJnTEhaRFJYbG1RdktCeXRzeEFhT0JhelBtT0tLMkc3SEllS1dHTVctYU9pZ005a01WZUF6cXROaXp4RFNmLVZUSXFYWllSXy1reVU4OFlTU2YyaXl2dUU0Wm8?oc=5","date":"2025-12-05","type":"deal","source":"BioWorld News","summary":"Neurimmune inks deal to advance NI-009 for AL amyloidosis - BioWorld News","headline":"Neurimmune inks deal to advance NI-009 for AL amyloidosis","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMipAFBVV95cUxNWExheUJRcVBROURNTGRBanNHbjNmTDYyd251SktwTG9CMmtZWjQ4cFlOWGxOcTAzMVNXanYzMGVtU3NBc1R1eDBCajF3ckd1azVPWEg1VnM4cjNZSXhVNmZMMzBERmNSTVhnbUFIcndsS3JRRl9PWHdOdWJ4Y2NtNzdha05ucmp1eEJzdDFadUp4ajdQSmJGd1BOMXdZanduS1VWWA?oc=5","date":"2025-12-04","type":"pipeline","source":"Fierce Biotech","summary":"AstraZeneca's latest amyloidosis pact with Neurimmune could reach $780M - Fierce Biotech","headline":"AstraZeneca's latest amyloidosis pact with Neurimmune could reach $780M","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMilgJBVV95cUxQdnFnYWY2RldDblVidnduaGJTMnQ0Mm5NZGRaTC1kbGV3WHhPay1hYV8zTi1pLWJpdHFNc2dMVldDenBBOGhqX29mcjIxcEd4aGd3MERTeVpqWFcxZTlKMmhmcjVkRDdocExDWTdKZUYyZ2I5T0NKWEJBNDctWHpkRWQ5TDBFXzF0c3NxNXhrRUR2U3lNanRBNkxOWVRfNFZ2Mzd0RExkVGlXeUtDNmVoUkE2U3BndzFOVU5vdnRQRVhOWDVzVjF6cDZrWVR5VnJYUy1jd0RsYUFUSVZTTVFhS2FRVWNxWG1pTkxwUVhUMVFJSGZWWXZXaXNwNFM0dk41eHFxa3NwaC1sSlVuLWNyVEk1cEQ4dw?oc=5","date":"2025-09-25","type":"trial","source":"PR Newswire","summary":"AL-S Pharma Appoints Internationally Recognized Neurologist and Clinical Trial Expert Prof. Dr. Angela Genge as Chief Medical Officer - PR Newswire","headline":"AL-S Pharma Appoints Internationally Recognized Neurologist and Clinical Trial Expert Prof. Dr. Angela Genge as Chief Me","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMilAJBVV95cUxOVVh2S1A2RG52NUNMZEtWNlFVYXJIZ3ExWjh2WmVJZDl5X0ZCYzB3WTNwXzlMaTdGODFDMExGNHZHU3hzS2U4MkkxNXF6WW96aDZGalB4R3JpOV9HaTJqWjFMWHhBR185clNFWEpXT1ZpaFFVaks0ZnpoYmQ3YmlFbVc5N0FGNGRaeU96QWxqYnpNM2VaSC1kRXI0aVN0T0ZSblh6QkNvME5UcWJlRm9CTzBNRXpiWGNvVm83VGRNQjJJLUlMNl95WFFXRkoyaGxmQzFFbEVLWDJaMzA5aWFWLWllT0dKdnliOWhzeVlTaGtEaVMwZXhZcHYzdUxBME1WVE5xQ0ZZOXYzZy1tUlNLd0F3UzI?oc=5","date":"2025-09-04","type":"trial","source":"PR Newswire","summary":"AL-S Pharma announces positive topline results from Phase 2 study of AP-101 for the treatment of amyotrophic lateral sclerosis (ALS) - PR Newswire","headline":"AL-S Pharma announces positive topline results from Phase 2 study of AP-101 for the treatment of amyotrophic lateral scl","sentiment":"positive"},{"url":"https://news.google.com/rss/articles/CBMiqwFBVV95cUxQMGJxeFpJRmF2LUtOR2pmYnpaNXNvSVhFZTY2ZmtIVl9yTHpld2tvWFVhRXhUY3BYYy1TV1NSbnF6TzBPWTlDLWNjbE90bTJaVXQxUDRIX0JSNHQ0X1BHUWIxUlVrTWdQdmYwdTFKcHFzZ1dEZ1BKODhDb04tT0VRTXNzLUJJczV2V0dudlVTMVpKbFhsZ01MWkR5ckhGVnY2YmxuNGxGMFowWlE?oc=5","date":"2025-06-24","type":"deal","source":"Life Sciences Intellectual Property Review","summary":"AstraZeneca forced to clarify deal terms in row with university - Life Sciences Intellectual Property Review","headline":"AstraZeneca forced to clarify deal terms in row with university","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiyAFBVV95cUxOclhwallQalJMOU1JMU0yRFZsVTViRHNpU0FIRkkxdWlTbjZfQUVieDhEWlhrT2JNNkhpZXZFbkNWaTh4bUxVQ0EzREFOWjNqOXpWSHNFVkxwOW1JbFpwVjNTVXhieXF0LUxBN3NldG9ycW96VjB0d2VaQVNGdDNZX3JTak81MDNjTEIzYlBJUXh0MENJbTBUcWI0ZjFNQURWTXJ0X3FaenBRbFlVbHJmWFg0WkRZZkFBSFk0SENYeWRXT1Q4Q0c5Vg?oc=5","date":"2024-01-31","type":"pipeline","source":"Inside Precision Medicine","summary":"Biogen Will Refocus Its Alzheimer’s Pipeline and Stop Selling Aduhelm - Inside Precision Medicine","headline":"Biogen Will Refocus Its Alzheimer’s Pipeline and Stop Selling Aduhelm","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMisgFBVV95cUxOTXJlVUd3VTIxT0xuVG5LS3dmZk1yQldUVmk5NWo0UThXNU1LZWxiNjY0SmhjTmxZSHNSLXNkUmdwazY0NlNmNDhXMFMwa1laQTNoWWxqSEVuNnpaMnRxdDN0b25BV1N5NkJodHpHSjJIMFhsb1MyNnFPY0FVSGR0V0pnN01MaG53NlZxUmVmNklzbVZOaExVdkR1NThGQVhmeFRfcHI2bnFtTTJqdDlFWDhB?oc=5","date":"2022-01-07","type":"deal","source":"AstraZeneca","summary":"AstraZeneca and Neurimmune sign exclusive global collaboration and licence agreement to develop and commercialise NI006 - AstraZeneca","headline":"AstraZeneca and Neurimmune sign exclusive global collaboration and licence agreement to develop and commercialise NI006","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMijwFBVV95cUxQWGFWZ1g4LTI1dURqb0tXdFhKTnlNSTFHUnZ2cTJ1ellNVEZmaDVjOG03UXplQVNtczhvVDBaOFd0VUd4N1dwd1N6d0RHelljMjY3M0NBWXo4emJGRVJiR3F5WWlOQUg0MDFwVC1CTG1leU1lRTEwNEZ4REY3dEFLRnZ2bUpWMUFCNk1VVVd0dw?oc=5","date":"2017-10-24","type":"pipeline","source":"BioPharma Dive","summary":"Biogen doubling down on aducanumab - BioPharma Dive","headline":"Biogen doubling down on aducanumab","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi-wFBVV95cUxQUUtWVHpaMlBoUFJfZ3lwaTIzbklwUkNnT3gzb3FRNzdmcXFCOWJJbHpsMGhkRG1sTDJOY3ZCOGNyemVOcTBpNk55QUlXTHNORDg0eVlRU2lOdUZhYU1mejM2WGlfRlVVRzFWQnFONHpBOU9nOElKc3dNNXVSWGRfSXdDbS1oZjctVEcwQlJwRFJMR2g3RVVzQ0JDcUJPNExxVlhBY2U1S0Rya1FiWWpTdXFVRVNHTGgwall3QlNmN0Y5bUl2RTBjdzhjRFByb0NGLVZHVlBxajEyQmpKM2V2TFVzN3RFdnFfTW45UXRnNFQ5TWZUelVTSVM1MA?oc=5","date":"2016-12-08","type":"pipeline","source":"European Medical Journal","summary":"Neurimmune and TVM Capital Life Science Announce Creation of AL-S Pharma to Develop Innovative Therapy for Patients with ALS - European Medical Journal","headline":"Neurimmune and TVM Capital Life Science Announce Creation of AL-S Pharma to Develop Innovative Therapy for Patients with","sentiment":"neutral"}],"patents":[],"drugCount":1,"phaseCounts":{"phase_3":1},"enrichmentLevel":2,"visitCount":1,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}